Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022
CINCINNATI, Jan. 10, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022.
Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
If you are unable to join the webcast, you may join by telephone. From the U.S., dial (877) 407-0890, or from outside the U.S., dial (201) 389-0918, and provide the code 13726037.
A replay of the conference call will also be available by webcast for one year beginning 1:00 p.m. Eastern Time on February 4, 2022 using the link provided at investor.meridianbiocience.com.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
SOURCE Meridian Bioscience, Inc.